Nigel Farage piles pressure on Kemi Badenoch to apologise for her 'crazy conspiracy theory' that Reform's soaring membership numbers are fake By SABRINA PENTY Published: 18:00 GMT, 28 December 2024 | Updated: 19:20 GMT, 28 December 2024 e-mail 34 View comments Nigel Farage has urged Kemi Badenoch to apologise or face 'action' after she accused Reform UK of 'fakery' over its membership numbers. The Reform UK leader will spend the weekend weighing up what action to take if Conservative leader Mrs Badenoch ignores his calls for an apology over the 'crazy conspiracy theory'. Mr Farage pushed back against reports suggesting that le gal action would be the next step, as officials from both parties continued the row. The MP for Clacton also outlined his hopes that US billionaire Elon Musk could help attract younger voters to Reform as he 'makes us cool'. Tech entrepreneur Mr Musk met Mr Farage earlier this month at US President-elect Donald Trump 's Mar-a-Lago resort in Florida , amid rumours of a possible donation to either Mr Farage or Reform. Tensions between Reform and the Conservatives escalated after Mrs Badenoch accused Mr Farage of 'fakery' in response to Reform claiming they had surpassed the Tories in signed-up members. Mrs Badenoch said Reform's counter was 'coded to tick up automatically'. A digital counter on the Reform website showed a membership tally before lunchtime on Boxing Day ticking past the 131,680 figure declared by the Conservative Party during its leadership election earlier this year. Nigel Farage has urged Kemi Badenoch to apologise or face 'action' after she accused Reform UK of 'fakery' over its membership numbers Earlier this week Mrs Badenoch accused Mr Farage of 'fakery' in response to Reform claiming they had surpassed the Tories in signed-up members Mr Farage took to X today demanding an apology Mr Farage, in a statement issued on Mr Musk's social media site X, said the accusations of 'fraud and dishonesty' made against him were 'disgraceful'. He said Reform had opened up its systems to media outlets, including The Daily Telegraph and The Financial Times, in the 'interests of full transparency to verify that our data is correct'. He added: 'I am now demanding Kemi Badenoch apologises.' Mr Farage, on whether he was threatening legal action or not, told the PA news agency: 'I haven't threatened anything. I've just said that unless I get an apology, I will take some action. 'I haven't said whether it's legal or anything.' He added: 'All I've said is I want an apology. If I don't get an apology, I will take action. 'I will decide in the next couple of days what that is. So I've not specified what it is.' Mr Farage went on: 'She (Mrs Badenoch) has put out this crazy conspiracy theory and she needs to apologise.' In a provocative move, Mr Farage's upstart Right-wing party projected an image of its tally of paid supporters on the facade of Tory HQ in London during the night – showing it had apparently outstripped the 131,680 declared by its much older rival in its recent leadership contest On why Mrs Badenoch had reacted as she did, Mr Farage said: 'I would imagine she was at home without anybody advising her and was just angry.' Earlier today, Mr Farage also took to X to demand an apology from Mrs Badenoch. 'Good morning @KemiBadenoch. When will you apologise to me and 146,077 other members of Reform UK?', he wrote. On Saturday, Reform deputy leader Richard Tice appeared to push back further against suggestions of legal action, saying he hoped Mrs Badenoch would 'do the right thing' and apologise. He added: 'Otherwise I suspect she'll have 120 Tory MPs behind her aghast at her misstep during this festive season.' But Mr Tice also conceded that not every Reform member was necessarily entitled to vote in the UK, saying there was a difference between being joining a political party and being eligible to vote. A Conservative Party source claimed Mr Farage was 'rattled' that his Boxing Day 'publicity stunt is facing serious questions'. They added: 'Like most normal people around the UK, Kemi is enjoying Christmas with her family and looking forward to taking on the challenges of renewing the Conservative Party in the New Year.' Read More Kemi Badenoch and Nigel Farage go to war over Reform's membership numbers Mrs Badenoch, in a series of messages posted on X on Boxing Day, said: 'Farage doesn't understand the digital age. This kind of fakery gets found out pretty quickly, although not before many are fooled.' There were 131,680 Conservative members eligible to vote during the party's leadership election to replace Rishi Sunak in the autumn. Mrs Badenoch claimed in her thread that 'the Conservative Party has gained thousands of new members since the leadership election'. Elsewhere, Mr Farage used an interview with the Daily Telegraph newspaper to describe Mr Musk as a 'bloody hero'. He said: 'The shades, the bomber jacket, the whole vibe. Elon makes us cool - Elon is a huge help to us with the young generation, and that will be the case going on and, frankly, that's only just starting. 'Reform only wins the next election if it gets the youth vote. The youth vote is the key.' Share or comment on this article: Nigel Farage piles pressure on Kemi Badenoch to apologise for her 'crazy conspiracy theory' that Reform's soaring membership numbers are fake e-mail Add commentThe Los Angeles Clippers medical team has confirmed that Leonard's injury is a Grade 2 quadriceps strain, which typically requires a six-week recovery period. This means that Leonard will be out of action for an extended period, missing several important games and potentially impacting the team's ranking in the Western Conference.
As Chelsea continue their quest for glory in the Premier League and on the European stage, one thing is clear: they are a team on a mission, driven by a relentless desire to succeed and a hunger for victory. With their attacking firepower in full force and their team spirit at an all-time high, the Blues are a force to be reckoned with, and a joy to watch for football fans everywhere.Us Weekly has affiliate partnerships. We receive compensation when you click on a link and make a purchase. Learn more! The “best” often comes with an unattainable price tag, and Dyson is one of those brands that always felt just a little out of reach — until now. Not only is the coveted stick vacuum nearly 40% off during Amazon’s Black Friday Week sale, Dyson secretly slashed prices on multiple bestsellers including its air purifier and hair stylers. At these prices, these deals are too good not to share. Between pets, kids or an older home, keeping everything dust, dander and dirt-free feels like an impossible feat. I’m definitely scooping up the cordless, lightweight vacuum cleaner while it’s $250! If you’ve also been waiting, consider this your sign to shop before they’re out of stock. There are so many other deeply discounted Dyson bestsellers on sale right now. We put together a few top picks for you to shop now. Do they also make great gifts? We say yes! The Best Dyson Black Friday Week Deals on Amazon Dyson V7 Advanced Cordless Stick Vacuum Cleaner Cordless, runs for 30 minutes before needing a charge and $250 off? Yes, please. This stick vacuum transforms into a handheld model for cleaning little spills and extends to get those annoying ceiling cobwebs. That’s the kind of versatility we appreciate from just one easy-to-store appliance. Reviewers rave it’s the perfect vacuum. One shopper says , “I still love this vacuum! It’s still in perfect condition. So easy to use, especially under the beds and corners. I bought this months ago and waited to write a review because I wanted to get good use of it first. It’s the best vacuum for pet owners!!” Dyson V11 Origin Cordless Vacuum If you’re looking for a more powerful vacuum, the V11 is also convertible but offers extra features and power. The 39% off Dyson vacuum boasts three modes, features a high-tech LCD screen and captures 99.99% of particles so you can breathe free. This model also comes with extra accessories and detangles hair as it cleans. Dyson Airstrait Hair Straightener Scoop up a $99 coupon on Amazon for this cult-favorite hair straightener from Dyson. Stop paying for blowouts and get the tool that takes your hair from wet to dry without damage. Reviewers say it’s so easy to use and completely worth the spend. Just click the coupon box to earn the savings! Dyson Air Purifier and Fan Ideal for homes with pets or allergy sufferers, this HEPA filter-equipped fan purifies the air while doubling as a cooling fan. You can use just the air purifier for year-round maintenance. Again, we love multi-tasking appliances! Shoppers boast, “It works great as both a purifier and a fan. Really like that you can see how bad the air quality is at any given time. Has become an essential in my household.” Get it for $200 off on Amazon! Dyson Ball Animal 2 Total Clean Upright Vacuum Check our latest news in Google News Check our latest news in Apple News If you prefer an upright model, here’s your best pick that’s currently discounted at a whopping $250 off. The brand says it has the strongest suction of any vacuum! With a built-in HEPA filter, this corded vac is meant to clean larger homes that need regular deep cleaning. It has a self-adjusting cleaner head to move seamlessly between hard floors and carpet, and it comes with eight accessories.
However, as the day unfolded, it became clear that the tour was nothing more than a well-crafted facade designed to deceive and exploit unsuspecting tourists. Instead of visiting the promised destinations, the tour bus made a sudden detour to a remote area, far removed from any recognizable landmarks.Scholastic Corporation Announces Third Quarter DividendNews of the boy's untimely demise spread like wildfire, igniting a wave of sorrow and outrage across the city. People from all walks of life came together, united in their grief and disbelief. Candlelight vigils were held, prayers were whispered, and calls for justice echoed through the city's alleys and boulevards.
Amazon Quietly Dropped So Many Dyson Bestsellers to Prime Day PricesAn Invitation, A Rejection, Now What? Trump And Xi Jinping Play Mindgames
Us Weekly has affiliate partnerships. We receive compensation when you click on a link and make a purchase. Learn more! The best gifts often come in small packages. Whether you’re looking for a stocking stuffer or small yet impressive gift, we found just the item. These stunning, stackable bracelets are just $14 on Amazon! The dainty and sophisticated stack includes four gold-plated bracelets, including a gold bangle, kont cuff, paperclip bracelet and beaded bracelet. Each one is crafted with durable brass that shoppers say doesn’t tarnish or leave behind a green finish on skin. You can wear them all day long with ease thanks to the lobster claw clasps that keeps them in place. The elegant bracelets remind us of similar picks that cost triple their price. Get the Reoxvo Gold Bracelets Stack for $14 (originally $19) at Amazon1 “These bracelets were a great addition to my jewelry collection,” one five-star reviewer writes . “I’ve worn them in the shower. I’ve worn them to the beach and they still haven’t turned as of yet. They’re durable, made well and really pretty. I also like that they go with just about anything, and there’s lots of options to choose from.” “These bracelets look very similar to a designer brand I’ve been eyeing for awhile,” another reviewer shares . “I saw these on Instagram and decided to try, and I’m not disappointed. They look great and stylish.” Stackable bracelets that stand the test of time are hard to come by at this price, so hurry and order while they’re marked down! Check our latest news in Google News Check our latest news in Apple News Get the Reoxvo Gold Bracelets Stack for $14 (originally $19) at Amazon1
Jurgen Klopp, the charismatic and tactically astute manager of Liverpool FC, has been a guiding force behind the recent success of the club. With his infectious passion for the game and unwavering belief in his players, Klopp has helped transform Liverpool into a formidable team that can compete with the best in the world.GPI Stock Soars to All-Time High, Reaching $422.92
A new species of sicydiine goby named Stiphodon chlorestes is pictured in an undated photograph.Photo courtesy of National Sun Yat-sen University DISCOVERY:The small goby was first recorded in northern Taiwan in 2012, but improper storage of samples prevented the fish from being officially named By Huang Liang-chieh and Esme Yeh / Staff reporter, with staff writer A new species of fish has been discovered and named Stiphodon chlorestes by a research team from National Sun Yat-sen University (NSYSU). The research team led by Liao Te-yu (廖德裕), a professor of oceanography at NSYSU, identified the new species among specimens collected from rivers in Taiwan and northern Luzon in the Philippines. The research project was funded by the National Science and Technology Council and titled “Research on Habitat Assessments and Ecological Restoration Indicators of Isolated Creeks, with Three Rivers near the Northeast Coast as an Example.” Published in the Journal of Fish Biology in June, the research has garnered international attention and galvanized people into discussing habitat conservation of isolated creeks. The new species was first recorded in northern Taiwan in 2012, but it was not officially named due to improper storage of the specimen, said Chuang Wei-cheng (莊維誠), a NSYSU Department of Oceanography doctoral student. With more specimens collected in Taiwan and the Philippines for further research, the NSYSU research team finally identified the new species and gave it a name for the first time, he said. S chlorestes is a small migratory species of sicydiine goby, characterized by an olive-green body, a longitudinal band of dark brown oval spots on the sides, black and white spots on the pectoral fins and a short red or orange line on the caudal fin, as well as a metallic blue glow on the head of males. The fish was named S chlorestes, as it swims with its pectoral fins moving quickly, similar to a hummingbird flapping its wings, while the blue head and green body are reminiscent of the South African hummingbird Chlorestes cyanus. Isolated creeks — which run quickly from mountains into the ocean with a smaller basin area and fewer affluents — are habitats to various migratory fish, including Syngnathus, Stiphodon and Tetraroge niger. As research on fish diversity of isolated creeks continues to develop, more new species of migratory fish have been discovered, helping to promote the conservation of local isolated creek ecosystems. 新聞來源: TAIPEI TIMES 不用抽 不用搶 現在用APP看新聞 保證天天中獎 點我下載APP 按我看活動辦法M State opens new health sciences simulation center
SAN DIEGO , Dec. 13, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved CRENESSITYTM (crinecerfont) capsules and oral solution as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (CAH), a rare, serious and lifelong genetic condition involving the adrenal glands. CRENESSITY, a potent and selective oral corticotropin-releasing factor type 1 receptor (CRF 1 ) antagonist, is the first and only classic CAH treatment that directly reduces excess adrenocorticotropic hormone (ACTH) and downstream adrenal androgen production, allowing for glucocorticoid dose reduction. It is a breakthrough in the treatment landscape for classic CAH. "For the last three decades, Neurocrine Biosciences, together with our late founder, Wylie W. Vale , has conducted groundbreaking research uncovering the critical role of corticotropin-releasing factor and its receptor, CRF 1 , in the pathophysiology of congenital adrenal hyperplasia," said Kyle W. Gano , Ph.D., Chief Executive Officer, Neurocrine Biosciences. "The approval of CRENESSITY is a significant milestone for the CAH community, and we are grateful to the individuals who participated in our clinical trials, including their families and caregivers, and to the clinical investigators who helped advance a new therapy and class of medicines." "Patients and families struggle to achieve balance between managing the symptoms of CAH and the side effects or complications of treatment with high-dose steroids, which may impact quality of life," said Dina Matos , Executive Director, CARES Foundation. "We are grateful to Neurocrine Biosciences for engaging with our community throughout the drug development process to understand our needs and ultimately providing this new medication that can help reduce excess adrenal androgens and the need for high-dose steroid treatment for individuals living with CAH." CRENESSITY is expected to be commercially available in approximately one week. The medication will be provided through PANTHERx Rare, a specialty pharmacy, to centralize and simplify CRENESSITY prescription fulfillment. Neurocrine Biosciences is committed to supporting patients in obtaining treatment with CRENESSITY by offering Neurocrine Access Support, a free, comprehensive assistance program created for patients, caregivers and healthcare providers. It offers a range of options to make sure patients have everything they need to begin and continue taking CRENESSITY. A dedicated Care Coordinator, backed by a team, is available to help patients and caregivers navigate the insurance process and identify appropriate financial assistance options. Most patients will pay $10 or less per month for CRENESSITY*. For more information, visit www.NBIaccess.com/crenessity or call 1-855-CRNSITY (276-7489) Monday-Friday 8 am-8 pm ET . *Additional terms and conditions apply. CAHtalyst TM Clinical Program Overview: The FDA approval is supported by the largest-ever clinical trial program of classic CAH, the CAHtalyst Pediatric and Adult Phase 3 global registrational studies. CAHtalyst Phase 3 data results in pediatric and adult patients with classic CAH were published in The New England Journal of Medicine . "The clinical results across both CAHtalyst studies support the efficacy and safety profile of CRENESSITY and its ability to reduce the overproduction of adrenal androgens, allowing for a meaningful reduction in glucocorticoid dosage, while maintaining or enhancing control of these androgens," said Richard Auchus , M.D., Ph.D., Professor, University of Michigan Health, Principal Investigator. "Chronic treatment with supraphysiologic glucocorticoids can cause a number of short- and long-term health consequences, such as obesity, hypertension and osteoporosis, so the ability for patients with CAH to lower their glucocorticoid dose to a more physiologic level can have profound benefits." In both CAHtalyst studies, CRENESSITY enabled lower steroid doses and decreased androgen levels. Phase 3 CAHtalyst Pediatric Study: Phase 3 CAHtalyst Adult Study: CRENESSITY was well tolerated with few treatment-related adverse events in both CAHtalyst studies. Pediatric and adult patients taking CRENESSITY had no treatment-related serious adverse events. Adrenal insufficiency and crisis are risks of living with CAH that CRENESSITY does not address and can occur when a patient's GC dose is too low. In the CAHtalyst Pediatric study, there were no cases of adrenal crisis among patients taking CRENESSITY or placebo. In the CAHtalyst Adult study, two patients (1.6%) taking CRENESSITY experienced adrenal crisis. No patients on placebo experienced adrenal crisis. However, one patient (1.7%) on placebo experienced adrenal insufficiency. Patients should work with their healthcare provider to manage GC dosing while taking CRENESSITY. For more information about CRENESSITY, visit Crenessity.com . About Congenital Adrenal Hyperplasia Congenital adrenal hyperplasia (CAH) is a rare genetic condition that results in an enzyme deficiency that alters the production of adrenal steroid hormones, such as cortisol, aldosterone and adrenal androgens, which are essential for life. Approximately 95% of CAH cases are caused by variants of the CYP21A2 gene that leads to deficiency of the enzyme 21-hydroxylase (21-OH). Severe deficiency of this enzyme leads to an inability of the adrenal glands to produce enough cortisol and, in approximately 75% of cases, aldosterone. Because individuals with CAH are still able to produce androgens, the unused precursors that would normally be used to make cortisol instead result in the production of excess amounts of androgens. If left untreated, CAH can result in salt wasting, dehydration and even death. Historically, exogenous glucocorticoids (GCs) have been used not only to correct the endogenous cortisol deficiency, but doses used are higher than cortisol replacement needed (supraphysiologic) to lower the levels of adrenocorticotropic hormone (ACTH) and adrenal androgens. However, GC treatment at high doses has been associated with serious and significant complications of steroid excess, including metabolic issues such as weight gain and diabetes, cardiovascular disease and osteoporosis. Additionally, long-term treatment with high-dose GCs may have psychological and cognitive impact, such as changes in mood and memory. Adrenal androgen excess has been associated with abnormal bone growth and development in pediatric patients, female health problems such as excess facial hair growth and menstrual irregularities, testicular rest tumors in males and fertility issues in both sexes. About The CAHtalystTM Studies The Phase 3 CAHtalystTM global registrational studies were designed to evaluate the safety, efficacy and tolerability of CRENESSITY in children and adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The CAHtalyst studies were the largest-ever clinical trial program in classic CAH, including 285 pediatric and adult patients. The CAHtalyst Pediatric study included 103 pediatric patients aged four to 17 years. The study tested two questions. The first question evaluated whether four weeks of CRENESSITY treatment could improve androgen control. The second question evaluated whether an additional 24 weeks of CRENESSITY treatment enabled customized glucocorticoid (GC) down-titration while androstenedione levels were maintained or improved. The CAHtalyst Adult study included 182 adult patients aged 18 to 58 years. Similarly, the first question of the study evaluated whether four weeks of CRENESSITY treatment could improve androgen control, and the second question evaluated whether an additional 20 weeks of CRENESSITY treatment enabled GC reduction to physiologic range while androstenedione levels were maintained or improved. Data from the CAHtalyst Phase 3 studies supported approval of CRENESSITY by the U.S. Food and Drug Administration in December 2024. The open-label extension treatment portions of both studies are ongoing. About CRENESSITYTM (crinecerfont) CRENESSITYTM is a potent and selective, oral corticotropin-releasing factor type 1 receptor (CRF 1 ) antagonist developed to reduce and control excess adrenocorticotropic hormone (ACTH) and adrenal androgens through a non-glucocorticoid (GC) mechanism for the treatment of classic congenital adrenal hyperplasia (CAH). Antagonism of CRF 1 receptors in the pituitary has been shown to decrease ACTH levels, which in turn decreases the production of adrenal androgens and potentially the symptoms associated with CAH. The robust clinical study data demonstrate that lowering adrenal androgen levels with CRENESSITY enables lower, more physiologic dosing of GCs to replace missing cortisol. CRENESSITY comes in capsules and an oral solution. The capsule formulation is available in 50 mg and 100 mg doses. The oral solution is available as a 50 mg/mL strength formulation. For adults 18 years and older, the recommended dosage is 100 mg twice daily taken orally with a meal. For pediatric patients four to 17 years of age weighing less than 55 kg (121 lbs), the recommended dosage is based on body weight and is administered twice daily, taken orally with a meal. For pediatric patients weighing more than 55 kg (121 lbs), the recommended dosage is 100 mg twice daily taken orally with a meal. Healthcare providers can work with patients to determine the appropriate formulation for use depending on patient needs. Patients receiving CRENESSITY should continue GC therapy for cortisol replacement. Important Information Approved Uses CRENESSITY (crinecerfont) is a prescription medicine used together with glucocorticoids (steroids) to control androgen (testosterone-like hormone) levels in adults and children 4 years of age and older with classic congenital adrenal hyperplasia (CAH). IMPORTANT SAFETY INFORMATION Do not take CRENESSITY if you: Are allergic to crinecerfont, or any of the ingredients in CRENESSITY. CRENESSITY may cause serious side effects, including : Allergic Reactions. Symptoms of an allergic reaction include tightness of the throat, trouble breathing or swallowing, swelling of the lips, tongue, or face, and rash. If you have an allergic reaction to CRENESSITY, get emergency medical help right away and stop taking CRENESSITY. Risk of Sudden Adrenal Insufficiency or Adrenal Crisis With Too Little Glucocorticoid (Steroid) Medicine. Sudden adrenal insufficiency or adrenal crisis can happen in people with congenital adrenal hyperplasia who are not taking enough glucocorticoid (steroid) medicine. You should continue taking your glucocorticoid (steroid) medicine during treatment with CRENESSITY. Certain conditions such as infection, severe injury, or shock may increase your risk for sudden adrenal insufficiency or adrenal crisis. Tell your healthcare provider if you get a severe injury, infection, illness, or have planned surgery during treatment. Your healthcare provider may need to change your dose of glucocorticoid (steroid) medicine. Before taking CRENESSITY, tell your healthcare provider about all of your medical conditions, including if you are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. Tell your healthcare provider about all the medicines you take , including prescription and over-the counter medicines, vitamins, and herbal supplements. The most common side effects of CRENESSITY in adults include tiredness, headache, dizziness, joint pain, back pain, decreased appetite, and muscle pain. The most common side effects of CRENESSITY in children include headache, stomach pain, tiredness, nasal congestion, and nose bleeds. These are not all the possible side effects of CRENESSITY. Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088. Dosage Forms and Strengths: CRENESSITY is available in 50 mg and 100 mg capsules and as an oral solution of 50 mg/mL. Please see full Prescribing Information About Neurocrine Biosciences, Inc. Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com , and follow the company on LinkedIn , X (formerly Twitter) and Facebook . (*in collaboration with AbbVie) The NEUROCRINE BIOSCIENCES Logo Lockup and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc. CRENESSITY and CAHtalyst are trademarks of Neurocrine Biosciences, Inc. Forward-Looking Statements In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the potential benefits to be derived from CRENESSITY for the treatment of classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency; the value and benefits CRENESSITY brings to patients with CAH; the ability of Neurocrine Biosciences to ensure patients have access to CRENESSITY; and whether the results from our clinical trials of CRENESSITY are indicative of real-world results. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, as well as risks and uncertainties associated with the commercialization of CRENESSITY; whether CRENESSITY receives adequate reimbursement from third-party payors; the degree and pace of market uptake of CRENESSITY; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; risks associated with the Company's dependence on third parties for development and manufacturing activities related to CRENESSITY, and the ability of the Company to manage these third parties; risks that additional regulatory submissions for CRENESSITY or other product candidates may not occur or be submitted in a timely manner; risks that the FDA or other regulatory authorities may make adverse decisions regarding CRENESSITY; risks that post-approval CRENESSITY commitments or requirements may be delayed; risks that CRENESSITY may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission, including without limitation the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2024 . Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than required by law. © 2024 Neurocrine Biosciences, Inc. All Rights Reserved. CP-CFT-US-0070 12/2024 View original content to download multimedia: https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-fda-approval-of-crenessity-crinecerfont-a-first-in-class-treatment-for-children-and-adults-with-classic-congenital-adrenal-hyperplasia-302331772.html SOURCE Neurocrine Biosciences, Inc.
The cold weather in Beijing today calls for extra layers of clothing to keep the body warm. It is important to dress appropriately for the low temperatures to avoid catching a cold or falling sick. Wearing thermal undergarments, wool sweaters, scarves, gloves, and hats can help to retain body heat and protect from the chilly winds.In response to the escalating situation, the Greenland Group took immediate action by filing a formal complaint with the authorities and launching an internal investigation to ascertain the truth behind the allegations. The company's spokesperson vehemently denied the accusations, stating that the Chairman has no involvement in any inappropriate behavior or activities as depicted in the circulated photos.B. Metzler seel. Sohn & Co. Holding AG Invests $1.71 Million in HubSpot, Inc. (NYSE:HUBS)
'I was stunned:' UNL Jersey Guy's viral fame nets him big gift from FanaticsAs 2025 is around the corner, the field of data science is all set for a transformative leap. With the convergence of cutting-edge technologies like artificial intelligence, machine learning, and the Internet of Things (IoT), the possibilities for data science are expanding exponentially. As we look ahead to the next horizon, several key trends are emerging that will shape the future of data science and redefine the landscape for professionals in this field. In this article, we'll look at the top trends that will dominate the data science landscape in 2025 and beyond. AI is already spearheading a revolution in data science, and by 2025, it will probably be more than household ownership. According to a report compiled by PwC , 45 percent of all jobs could be automated by the time we reach 2025 due to AI in Data Science, and data scientists will further lean on AI tools for routine tasks such as data cleaning and model selection. In the future of data science, machine learning models will be made accessible, allowing even small businesses to use sophisticated AI with their respective data analysis demands. The way data scientists do their work will be future AutoML tools in 2025, as the entire industry and all other parameters will increase by including the shape of automation in machine learning model construction. Therefore, AutoML is the hottest cake for all corporates who want data-driven decision-making about their business without forming a battery of specialized experts. According to McKinsey , the consensus regarding the increasing propensity for AutoML usage over the years is that its use will grow by 50% in the future. As per some Data Science Predictions 2025, more companies are expected to increasingly adopt AutoML in developing machine learning models, thus enabling them to act quickly with decisions for better customer experiences. These platforms would be considerably less daunting for non-technical professionals to use machine learning. Above all, great questions like privacy or security will also come with increasing concern for the former and ethical considerations in the fledgling data science area. The likes of GDPR and CCPA are just opening treaties or regulations. Those data scientists must ensure that AI and machine learning algorithms comply with such standards since they will expand and change in time. Last year, an Accenture survey found that 70% of consumers wanted to know how companies use their data. Thus, data scientists will have to find more transparent and accountable models. Data visualization would go far beyond tables and graphs by 2025. The demand for such great things in visualization would be more immersive and interactive than the simple, symbolic rendering of complex data shapes by which people could interactively engage such data with their exploration. Virtual Reality (VR) and Augmented Reality will become concepts that mainstream data scientists will use to investigate huge datasets in 3D. The data science landscape promises unprecedented growth in 2025, driven by the convergence of AI, automation, data privacy, and advanced visualization technologies. Professionals who stay ahead of the curve and adapt to these evolving trends will be uniquely positioned to thrive in this dynamic environment. With its vast potential to transform industries and revolutionize decision-making, the future of data science has never been brighter. It’s quite clear that the possibilities for data science in 2025 and beyond are limitless.